TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02215707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
Study: NCT03387709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pistachio-enriched diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General dietary guidance diet
Description: During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study: NCT01332591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI of significant stenoses of non-infarct coronary arteries
Study: NCT01574820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg)/day
Description: rosiglitazone (4 mg)/day for 6 months
Study: NCT04381052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Dose is 25mg intravenously over 30 minutes.
Study: NCT03945578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor muscle training - PFMT
Description: Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral Manual Therapy - VMT
Description: Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
Study: NCT04381052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously administered over 30 minutes.
Study: NCT05392673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)
Description: Artificial liver scavenges inflammatory factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)
Description: Artificial liver scavenges inflammatory factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)
Description: Artificial liver scavenges inflammatory factors.
Study: NCT02840318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Intervention
Description: See arm description
Study: NCT04434430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Oral Gabapentin 600 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral NaCl 500 mg
Study: NCT03945578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Sham Therapy - MST
Description: The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
Study: NCT02061982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Description: Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee consumption
Description: Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
Study: NCT01208818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO group
Description: TheraliteTM dialyzer of 2.1 m2 in surface
Study: NCT02973217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Study: NCT04073069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The DR group
Description: Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The R group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT01725178

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and Physical training
Description: Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management.
Study: NCT03865056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow (High-flow Nasal Cannula)
Description: Optiflow will be applied for 20 minutes
Study: NCT01208818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional high-flux dialyzer
Description: conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
Study: NCT04341311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: - Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: - Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
Study: NCT03865056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Ventilation
Description: non-invasive ventilation will be applied for 20 minutes
Study: NCT05013593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Clover Extract (RCE)
Description: Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Clover Extract (RCE)
Description: Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
Study: NCT00887978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: treprostinil diolamine sustained release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02387866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Study: NCT03394105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrapleural docetaxel administration
Description: intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
Study: NCT00575107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standard training of leg extension
Study: NCT04341311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: - Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
Study: NCT02840734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
Study: NCT02062970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood draw
Study: NCT00549406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computerized visual training
Description: two one-hour training sessions per week, for five consecutive weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: computerized word puzzles
Description: two one-hour sessions per week, for five consecutive weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-game based visual training
Description: two one-hour training sessions per week, for five consecutive weeks
Study: NCT02335034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Group Educational courses, DVD, print material of lectures
Description: 2 Educational courses (two months apart). Receive DVD and printed material of the lectures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group only make evaluations / consultations with all professional teams
Description: Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years.
Study: NCT03427866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
Study: NCT03766113

Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback coupling electroencephalogram and functional MRI in time actual
Description: One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording
Description: Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference.
Study: NCT02597751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO-OP)
Description: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention.
Study: NCT01691846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar+metformin
Description: 150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+metformin
Description: Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
Study: NCT01690416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional palpation technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional palpation technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound DNTP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound DNTP
Study: NCT00971724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, once daily, for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration
Study: NCT01340716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan exercise
Description: patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: patients in this group held weekly classes of two stretching for 12 weeks.
Study: NCT01367236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: * atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: novel treatment
Description: * darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily
Study: NCT03481751

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test: Ultrasound
Description: Transabdominal ultrasound of the bowel for categorization of disease activity
Study: NCT04420767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham brain stimulation
Description: Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Go-No GO task
Description: During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go-No GO task
Description: During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
Study: NCT03514836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVac/PCa
Description: Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: immunomodulatory medication given around the ONCOS-102 dosing
Study: NCT01083316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1
Study: NCT03304834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHOPULSE
Description: Patient are treated with the HIFU device and the physician is doing a compressive bandage.
Study: NCT04131907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Description: The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Description: The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Optilume Sham Device
Description: 21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
Study: NCT02187887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.